US-based Cerulean Pharma, a nanopharmaceutical company backed by Lilly Ventures, raises $13m from a consortium of previous backers, bringing the total raised by the drug company to $80m.
A consortium of previous backers has invested $13m into Cerulean Pharma, a clinical stage drug company. The investment is an extension of the $15m D round Cerulean raised in November which saw involvement from existing investors, Lilly Ventures, a corporate venturing unit of Eli Lilly, and venture firms Polaris Venture Partners, Venrock, Lux Capital and Bessemer Venture Partners.
The funds bring the total raised by Cerulean to more than $80m and the new investment will be used to complete clinical trials…
